A world leader in organ preservation
XVIVO's business concept is to develop and market effective, innovative technologies for preserving, assessing and transporting organs outside the body while awaiting transplant, and to facilitate the transplant process by offering service solutions to support hospitals.
-
Latest information
Latest LinkedIn news
Latest webcast
Latest highlights
Q1 2025 highlights
Net revenue, MSEK
198.5
(198.5)
Net revenue, MSEK
198.5
(198.5)
EBIT, MSEK
198.5
(198.5)
Net revenue, MSEK
198.5
(198.5)
Q1 2026 highlights
Net sales in Q1 2026, MSEK
241.0 (218.6)
Adjusted EBITDA in Q1 2026
21% (20%)
Organic growth in Q1 2026
23%
Our equity story
Continue through the remainder of this page to explore our full equity story — how XVIVO creates long-term value through innovative perfusion technologies and services, and its commitment to the vision that nobody should die waiting for a new organ.
XVIVO at a glance
Our technologies save organs so others can save lives
XVIVO's business concept is to develop and market effective, innovative technologies for preserving, assessing and transporting organs outside the body while awaiting transplant, and to facilitate the transplant process by offering service solutions to support hospitals.
Global market leadership
XVIVO is a global leader in lung preservation and perfusion, aiming for global leadership also for heart, liver and kidney.
Geographical sales distribution in 2025:
Geographical sales distribution in 2025:
Geographical sales distribution:
America
EMEA
Asia & Oceania
Comprehensive service offering
Beyond products, we provide organ recovery services, experienced perfusionists, and an advanced communication platform to support transplant clinics in optimizing their programs and overcoming logistical challenges.
Our strategic focus areas
Accelerate market leadership in lung
Change the paradigm of heart preservation
Become market leader in kidney perfusion
Accelerate market leadership in liver perfusion
Founded
1998
Number of employees:
~210
Headquarters in
Gothenburg
Sweden
Revenue in 2025 (SEK)
812M
Investment case
01
Machine perfusion – a new standard
XVIVO wants to change the world for all people in need of a new organ, guided by the vision that nobody should die waiting for a new organ. Today, only around 10% of global transplant needs are met. Machine perfusion is emerging as a new standard for transporting, preserving and assessing organs, addressing the limitations of traditional ice storage—where, for example, only two out of ten donated hearts are used.
XVIVO’s technologies for lungs, hearts, livers, and kidneys enable more donated organs to be utilized rather than discarded. As adoption grows, the market potential for machine perfusion is estimated to be up to ten times larger than that of conventional ice-based preservation.
XVIVO’s technologies for lungs, hearts, livers, and kidneys enable more donated organs to be utilized rather than discarded. As adoption grows, the market potential for machine perfusion is estimated to be up to ten times larger than that of conventional ice-based preservation.
02
Innovation that saves lives
and reduces healthcare costs
and reduces healthcare costs
XVIVO’s innovations enable more transplants while reducing costs for hospitals and healthcare systems. HOPE (hypothermic oxygenated perfusion) is an innovative preservation method for heart, liver and kidney, which XVIVO is the only company to offer for all three organs. Through HOPE, organs can be preserved and transported for significantly longer periods than is currently standard, enabling more donated organs to be used. XVIVO is the only company offering this method for all three organs.
Kidney transplantation highlights the economic benefits. In the US, kidney failure patients make up 1% of Medicare beneficiaries but account for 7% of costs. A transplant reduces expenses significantly, saving about two-thirds of dialysis costs over ten years. It also improves quality of life and increases life expectancy by an average of 15 years.
Kidney transplantation highlights the economic benefits. In the US, kidney failure patients make up 1% of Medicare beneficiaries but account for 7% of costs. A transplant reduces expenses significantly, saving about two-thirds of dialysis costs over ten years. It also improves quality of life and increases life expectancy by an average of 15 years.
03
Tailored service offerings
Long-term relationships in healthcare increasingly depend on integrated services. Many transplant centers face resource and logistical challenges that can limit activity. For this reason, XVIVO invests significant resources in developing service solutions and functioning as an extension of transplant teams.
Its offerings vary by market and include services such as organ recovery, perfusion, NRP, and the communication platform XVIVO FlowHawk, alongside its products. These services help clinics expand transplant programs, improve efficiency, and enhance patient outcomes. At the same time, they strengthen customer relationships and create a stable foundation for continued growth.
Its offerings vary by market and include services such as organ recovery, perfusion, NRP, and the communication platform XVIVO FlowHawk, alongside its products. These services help clinics expand transplant programs, improve efficiency, and enhance patient outcomes. At the same time, they strengthen customer relationships and create a stable foundation for continued growth.
04
Evidence-based technologies
Organ transplantation relies on trust in both the company and its technologies. In this highly regulated field, new products must be supported by clinical studies proving safety and effectiveness.
XVIVO’s technologies are backed by extensive clinical evidence published in leading journals such as The Lancet and New England Journal of Medicine. By continuously generating new data, XVIVO strengthens its credibility and reinforces its position as a trusted partner for transplant centers worldwide.
XVIVO’s technologies are backed by extensive clinical evidence published in leading journals such as The Lancet and New England Journal of Medicine. By continuously generating new data, XVIVO strengthens its credibility and reinforces its position as a trusted partner for transplant centers worldwide.
05
A business model for sustainable growth
XVIVO’s business model drives sustainable growth through innovation, clinical evidence, and close collaboration with transplant centers. Its technologies and services address key challenges by increasing organ use while reducing costs for healthcare systems and society.
In the coming years, XVIVO plans to launch its heart technology in Europe in 2026 and in the US in 2027, along with introducing liver perfusion technology in the US, the largest transplant market. These launches unlock significant market potential.
Together, this creates strong incentives for healthcare providers and policymakers to prioritize transplantation, strengthening XVIVO’s long-term growth prospects.
In the coming years, XVIVO plans to launch its heart technology in Europe in 2026 and in the US in 2027, along with introducing liver perfusion technology in the US, the largest transplant market. These launches unlock significant market potential.
Together, this creates strong incentives for healthcare providers and policymakers to prioritize transplantation, strengthening XVIVO’s long-term growth prospects.
Our three business areas
63% of total sales in 2025
Thoracic products
Lung
XPS™
STEEN Solution™
PERFADEX® Plus
Heart
XVIVO Heart Assist Transport™
XVIVO Heart Solution™
XVIVO Heart Solution Supplement™
CAUTION—Investigational device. Limited by Federal (United States) law to investigational use. The safety and effectiveness of this device have not been established.The XVIVO heart technology is not commercially available.
About Thoracic
The Thoracic business area includes XVIVO’s lung and heart transplant products.
In lung transplantation, XVIVO leads globally with PERFADEX Plus for cold preservation and XPS with STEEN Solution for assessment of lungs.
For heart transplantation, the heart technology comprises a machine, a disposable unit and a perfusion solution with a supplement customized for heart.
In lung transplantation, XVIVO leads globally with PERFADEX Plus for cold preservation and XPS with STEEN Solution for assessment of lungs.
For heart transplantation, the heart technology comprises a machine, a disposable unit and a perfusion solution with a supplement customized for heart.
About Thoracic
The Thoracic business area includes XVIVO’s lung and heart transplantation operations. In lung transplantation, XVIVO markets PERFADEX Plus for cold preservation and XPS with STEEN Solution for machine perfusion, where it is the global leader.
In heart transplantation, XVIVO is introducing a pioneering preservation technology expected to receive CE marking in the first half of 2025, enabling a European launch. Regulatory approval will also be pursued in Australia, with a streamlined process anticipated. A U.S. clinical study completed enrollment in November 2024, and one-year follow-up data is pending. The technology consists of a machine, disposables, and a specialized perfusion solution.
In heart transplantation, XVIVO is introducing a pioneering preservation technology expected to receive CE marking in the first half of 2025, enabling a European launch. Regulatory approval will also be pursued in Australia, with a streamlined process anticipated. A U.S. clinical study completed enrollment in November 2024, and one-year follow-up data is pending. The technology consists of a machine, disposables, and a specialized perfusion solution.
Revenue model
In both Thoracic and Abdominal, profitability is mainly driven by disposable sales rather than machines. Machine sales are treated as capital goods, with the aim of expanding the installed base for clinics starting or scaling up transplant programs.
Each installed machine—used for preservation, assessment, or transport—requires single-use disposables per organ. These consumables are the primary revenue source.
Gross margin in 2024 was strong: 85% for Thoracic machine perfusion and 65% for Abdominal.
Each installed machine—used for preservation, assessment, or transport—requires single-use disposables per organ. These consumables are the primary revenue source.
Gross margin in 2024 was strong: 85% for Thoracic machine perfusion and 65% for Abdominal.
67% of total sales in 2024
- Revenue modelWithin the Thoracic and Abdominal business areas, the objective is to increase the installed base of machines for all organs among customers aiming to start or expand their transplant programs. For each installed machine, regardless of whether it is intended for preservation, assessment of organs or transport, disposables are used for each handled organ. These disposables and solutions comprise the business areas’ main source of income, as they are considered one-time use consumables.
Profitability therefore lies in increasing the utilization rate per machine and thereby maximizing sales of consumables. Revenue from the machines themselves is not significant; machines are either sold, leased or loaned to customers depending on the situation and market. The gross margin is strong and amounted to 85 percent (85) for machine perfusion in Thoracic in 2025. In Abdominal, the gross margin was 61 percent (65).
28% of total sales in 2025
Abdominal products
Liver
Liver Assist™
Kidney
Kidney Assist Transport™
Kidney Assist™
About Abdominal
The Abdominal business area covers XVIVO’s liver and kidney technologies.
For liver transplantation, XVIVO markets Liver Assist, the leading perfusion technology in Europe.
For kidney transplantation, Kidney Assist Transport and Kidney Assist are used for machine perfusion.
In Italy, XVIVO also offers a perfusion service, with employed perfusionists supporting clinics in using the company’s technologies.
For liver transplantation, XVIVO markets Liver Assist, the leading perfusion technology in Europe.
For kidney transplantation, Kidney Assist Transport and Kidney Assist are used for machine perfusion.
In Italy, XVIVO also offers a perfusion service, with employed perfusionists supporting clinics in using the company’s technologies.
About Thoracic
The Thoracic business area includes XVIVO’s lung and heart transplantation operations. In lung transplantation, XVIVO markets PERFADEX Plus for cold preservation and XPS with STEEN Solution for machine perfusion, where it is the global leader.
In heart transplantation, XVIVO is introducing a pioneering preservation technology expected to receive CE marking in the first half of 2025, enabling a European launch. Regulatory approval will also be pursued in Australia, with a streamlined process anticipated. A U.S. clinical study completed enrollment in November 2024, and one-year follow-up data is pending. The technology consists of a machine, disposables, and a specialized perfusion solution.
In heart transplantation, XVIVO is introducing a pioneering preservation technology expected to receive CE marking in the first half of 2025, enabling a European launch. Regulatory approval will also be pursued in Australia, with a streamlined process anticipated. A U.S. clinical study completed enrollment in November 2024, and one-year follow-up data is pending. The technology consists of a machine, disposables, and a specialized perfusion solution.
Revenue model
In both Thoracic and Abdominal, profitability is mainly driven by disposable sales rather than machines. Machine sales are treated as capital goods, with the aim of expanding the installed base for clinics starting or scaling up transplant programs.
Each installed machine—used for preservation, assessment, or transport—requires single-use disposables per organ. These consumables are the primary revenue source.
Gross margin in 2024 was strong: 85% for Thoracic machine perfusion and 65% for Abdominal.
Each installed machine—used for preservation, assessment, or transport—requires single-use disposables per organ. These consumables are the primary revenue source.
Gross margin in 2024 was strong: 85% for Thoracic machine perfusion and 65% for Abdominal.
67% of total sales in 2024
- Revenue modelWithin the Thoracic and Abdominal business areas, the objective is to increase the installed base of machines for all organs among customers aiming to start or expand their transplant programs. For each installed machine, regardless of whether it is intended for preservation, assessment of organs or transport, disposables are used for each handled organ. These disposables and solutions comprise the business areas’ main source of income, as they are considered one-time use consumables.
Profitability therefore lies in increasing the utilization rate per machine and thereby maximizing sales of consumables. Revenue from the machines themselves is not significant; machines are either sold, leased or loaned to customers depending on the situation and market. The gross margin is strong and amounted to 85 percent (85) for machine perfusion in Thoracic in 2025. In Abdominal, the gross margin was 61 percent (65).
9% of total sales in 2025
Services
XVIVO Organ Recovery Service
XVIVO FlowHawk™
About XVIVO Services
In the U.S., XVIVO Services streamlines the transplant process to help clinics perform more transplants. The business includes XVIVO Organ Recovery Service and a digital communication platform, XVIVO FlowHawk.
XVIVO’s organ recovery teams are available 24/7 to recover thoracic organs and transport them to transplant centers. XVIVO FlowHawk software platform enables HIPAA-compliant direct communication with collaborating teams, ensuring that the right information reaches the right people at the right time. It is now available in the U.S. market.
XVIVO’s organ recovery teams are available 24/7 to recover thoracic organs and transport them to transplant centers. XVIVO FlowHawk software platform enables HIPAA-compliant direct communication with collaborating teams, ensuring that the right information reaches the right people at the right time. It is now available in the U.S. market.
About Thoracic
The Thoracic business area includes XVIVO’s lung and heart transplantation operations. In lung transplantation, XVIVO markets PERFADEX Plus for cold preservation and XPS with STEEN Solution for machine perfusion, where it is the global leader.
In heart transplantation, XVIVO is introducing a pioneering preservation technology expected to receive CE marking in the first half of 2025, enabling a European launch. Regulatory approval will also be pursued in Australia, with a streamlined process anticipated. A U.S. clinical study completed enrollment in November 2024, and one-year follow-up data is pending. The technology consists of a machine, disposables, and a specialized perfusion solution.
In heart transplantation, XVIVO is introducing a pioneering preservation technology expected to receive CE marking in the first half of 2025, enabling a European launch. Regulatory approval will also be pursued in Australia, with a streamlined process anticipated. A U.S. clinical study completed enrollment in November 2024, and one-year follow-up data is pending. The technology consists of a machine, disposables, and a specialized perfusion solution.
Revenue model
In both Thoracic and Abdominal, profitability is mainly driven by disposable sales rather than machines. Machine sales are treated as capital goods, with the aim of expanding the installed base for clinics starting or scaling up transplant programs.
Each installed machine—used for preservation, assessment, or transport—requires single-use disposables per organ. These consumables are the primary revenue source.
Gross margin in 2024 was strong: 85% for Thoracic machine perfusion and 65% for Abdominal.
Each installed machine—used for preservation, assessment, or transport—requires single-use disposables per organ. These consumables are the primary revenue source.
Gross margin in 2024 was strong: 85% for Thoracic machine perfusion and 65% for Abdominal.
67% of total sales in 2024
- Revenue modelThe revenue model for organ recovery consists of revenue per recovered organ. XVIVO offers US customers (hospitals) a high-quality complete solution that involves coordinating between donor hospital, recipient hospitals and OPO (Organ Procurement Organization), clinical organ recovery by a surgical team, and ground and air transport offered in collaboration with logistics partners. XVIVO offers organ recovery for all donor types, such as DBD and DCD, as well as Normothermic Regional Perfusion (NRP). Hospitals have flexibility in the scope of service, with most opting for a 24/7 solution, while others have chosen on-demand, one-off recovery services. Revenue from XVIVO FlowHawk is based on Software-as-a-Service (SaaS) model, meaning XVIVO provides the communication platform through a subscription-based offering. This model generates recurring revenue instead of one-time sales, contributing to a stable and predictable revenue stream over time.
Our market
- only 10% of global demand is met.
Low utilization of donated organs drives demand for machine perfusion. Approximately 1.7 million organ transplants needed each year. With only 170,000 organ transplants each year, only 10% of global demand is met.
Approximately
1.7 million
organ transplants needed each year.
With only
170,000
organ transplants each year.
Only
10%
of global demand is met.
Utilization rates of donated organs
After a donor has been identified and accepted, the organs are offered to transplant clinics. Unfortunately, it is rare for all donated organs to be recovered for transplantation.
Lung
20%
Heart
20%
Liver
75%
Kidney
70%
Factors that limits the use of marginal organs
Organ quality
The surgeon is uncertain whether the organ meets the necessary quality standards for a successful transplantation.
Capacity
Transplant clinics have limited resources for recovering donated organs and ensuring optimal preservation outside the body. There is also a shortage of perfusionists, the specialists responsible for handling perfusion machines.
Logistics
The limited time an organ can remain viable outside the body poses logistical challenges, restricting both the distance it can be recovered from and the most effective transportation method.
XVIVO’s products & services address the limitations of the current transplant system.
Macro trends driving demand
Transplantation offers lower alternative cost
Kidney transplants have been shown to generate significant cost savings for healthcare providers. A Swedish study¹ showed that if a patient receives a transplant instead for attending dialysis for 10 years, this generates savings of between 66-79 percent per patient for healthcare services. This change should also impact positively on patient quality of life, as dialysis can impact a patient’s day-to-day life.
Reports show that the health economic benefits of replacing organs on-demand are in line with curing cancer².
Reports show that the health economic benefits of replacing organs on-demand are in line with curing cancer².
1. Jarl et al., Clinical Kidney Journal, 2018
2. Giwa et al, Nat Biotechnol. 2017.
A growing and aging population
As the global population grows and life expectancy rises, the proportion of elderly people is increasing. This shift impacts both the supply and demand for organ transplants, with more elderly individuals now donating and receiving organs—age is no longer a limiting factor.
Increased health care costs
The healthcare sector is growing faster than the global economy. At the same time, funding is shifting toward public sources. This benefits transplantation, as high transplant volumes are typically found in markets with strong overall healthcare spending and low levels of private funding.
More people suffer from chronic disease
Chronic diseases are on the rise, driven by factors like smoking, poor diet, inactivity, and alcohol use. These conditions are the leading cause of organ failure, resulting in growing demand for transplants.
Strategy 2027
XVIVO believes in an extended life of organs and that nobody should die waiting for a new organ. Our 2023–2027 strategic period is grounded in these values. Our strategic objective is to become the preferred partner in the transplantation process.
The preferred partner in the transplantation process
XVIVO aims to be the preferred partner in the transplantation process by combining advanced organ preservation technologies with support, training, and service solutions to help clinics manage resource constraints.
Service models are becoming an increasingly important driver of growth in the transplantation market.
Three pillars for becoming the preferred partner in the transplantation process
The role of service offerings in our strategic focus areas
An important part of XVIVO’s strategy is to develop and invest in various service concepts that increase and facilitate the use of our technologies. These may include organ recovery, NRP evaluation and logistical solutions.
The importance of market access for increased adoption
XVIVO works to promote the health economic benefits of transplantation and drive improved reimbursement systems, supporting broader adoption by reducing costs and improving patient outcomes.
Building a world-class organization
XVIVO is focused on building a scalable commercial organization, particularly in the US, to support market access, reimbursement, and clinical adoption of its expanding organ portfolio.
Strategic focus areas
- Accelerate market leadership in lungWith over 25 years’ experience in lung transplantation, XVIVO is the clear market leader in both machine perfusion and static cold lung preservation. XVIVO developed EVLP technology, built the market for the assessment of donated lungs and has led its development. In the US, during 2025 XVIVO initiated a partnership with Perfusion Solution Inc. (PSI) with the aim of establishing perfusion hubs together with selected OPOs.
Its PERFADEX Plus solution is used by over 90% of transplant centers globally and continues to grow. - Change the paradigm of heart preservationXVIVO aims to become the market leader in preserving hearts outside the body and to make our technology the gold standard for preservation and transportation of donated hearts. The heart technology addresses the current limitation of only 3–4 hours of viability for a heart preserved on ice, which restricts transplant use. The technology using the HOPE method significantly extends preservation time, with clinical results showing successful transplants after over 12 hours. This innovation enables broader use of donor hearts and has the potential to transform the market. CE marking in Europe and FDA submission in the US are planned for 2026.
- Become market leader in kidney perfusionKidney transplantation is the most common organ transplant globally, and XVIVO is driving innovation in this established market with its Kidney Assist Transport using the HOPE method. The portable system is approved in Europe and the US and is gaining traction, particularly in Europe’s growing DCD segment. Further modifications are underway to support a broader US launch, expected in 2027.
- Accelerate market leadership in liver perfusionXVIVO is the market leader in liver perfusion in Europe, with its Liver Assist technology supported by strong clinical evidence, where clinical studies have shown improved organ survival, generate cost savings for hospitals, and enable extended preservation times. The company aims to further strengthen its position while expanding into the US, the world’s largest liver transplant market, where the product is not yet launched. XVIVO is currently exploring faster regulatory pathways with the FDA to accelerate market entry and unlock this significant commercial opportunity.
Christoffer Rosenblad
CEO
Lena Hagman
Deputy CEO & COO
Johan Holmström
Senior Vice President, Commercial Europe & RoW
Kristoffer Nordström
CFO / SVP Corporate Strategy & Business Development
Mark Reade
Senior Vice President, North America
Jaya Tiwari
Senior Vice President, Medical Affairs
Ylva Vihøj
Senior Vice President, Human Resources
Gösta Johannesson
Chairman of the Board and of the Remuneration Committee
Emil Billbäck
Member of the Remuneration committee
Göran Dellgren
Member of the Audit Committee
Anne-Karen Hunt
Member of the Board
Paul Marcun
Member of the Board
Erik Strömqvist
Member of the Audit Committee
Camilla Öberg
Chairman of the Audit Committee
Management & board
Christoffer Rosenblad
CEO
Christoffer Rosenblad
CEO
Bio:
Born 1975, M. Sc. Mech. Eng. and B. Sc. Fin Ec. Previously Acting CEO, COO, CFO and Head of North America at XVIVO, before that financial positions at Ciba Vision Nordic AB and LG Electronics.
See this page for updated shareholdings.
Close
Born
1975
Read bio
Christoffer Rosenblad
CEO
Lena Hagman
Deputy CEO & COO
Lena Hagman
Deputy CEO & COO
Bio:
Born 1965, B.Sc. in Chemistry and Textile Engineering from Chalmers University of Technology, Gothenburg. Previously Executive Vice President for Quality compliance, Regulatory and Medical Affairs at Getinge group for 7 years, and before that more than 20 years in leading positions with global responsibilities in R&D, supply chain and quality/regulatory/medical affairs within the medical device industry.
See this page for updated shareholdings.
Close
Born
1965
Read bio
Lena Hagman
Deputy CEO & COO
Johan Holmström
Senior Vice President, Commercial Europe & RoW
Johan Holmström
Senior Vice President, Commercial Europe & RoW
Bio:
Born 1970, M. Sc. Business Administration and Finance at University of Gothenburg. Previously Executive VP Marketing at Permobil, before that various senior management positions within sales, marketing and business development at Lohmann & Rauscher and Mölnlycke Health Care.
See this page for updated shareholdings.
Close
Born
1970
Read bio
Johan Holmström
Senior Vice President, Commercial Europe & RoW
Kristoffer Nordström
CFO / SVP Corporate Strategy & Business Development
Kristoffer Nordström
CFO / SVP Corporate Strategy & Business Development
Bio:
Born 1985, M. Sc. Business and Economics from University of Borås. Previously Head of Accounting and Controlling at XVIVO, before that Senior Manager and Authorized Public Accountant at KPMG Sweden.
See this page for updated shareholdings.
Close
Born
1985
Read bio
Kristoffer Nordström
CFO / SVP Corporate Strategy & Business Development
Mark Reade
Senior Vice President, North America
Mark Reade
Senior Vice President, North America
Bio:
Born 1963, MBA at Western University, London, Canada; B. Comm (Marketing) and BA (Economics) at McGill University, Montreal, Canada. Former President of Atos Medical, Inc, EVP of Global Sales at IMRIS, Inc., Regional VP with Medtronic Neuromodulation and Area Director (Canada) of Howmedica, Inc.
See this page for updated shareholdings.
Close
Born
1963
Read bio
Mark Reade
Senior Vice President, North America
Jaya Tiwari
Senior Vice President, Medical Affairs
Jaya Tiwari
Senior Vice President, Medical Affairs
Bio:
Born 1987, B.S. Neural Science candidate at New York University and PICTOR (Pulmonary & Intensive Care Translational Outcomes Research) Scholar at Columbia University. Previously North American Clinical Affairs Director and Clinical Research Program Manager at XVIVO, before that published Senior Research Program Manager at University of Pennsylvania and Columbia University overseeing studies in organ perfusion, transplant, and oncology.
See this page for updated shareholdings.
Close
Born
1987
Read bio
Jaya Tiwari
Senior Vice President, Medical Affairs
Ylva Vihøj
Senior Vice President, Human Resources
Ylva Vihøj
Senior Vice President, Human Resources
Bio:
Born 1970. M.Sc. Business Administration and Economics, International Business Program at Gothenburg School of Economics & Commercial Law, Gothenburg University. Previously Vice President for HR and Internal Communications at TitanX, and before that more than 20 years in leading positions with global responsibility in HR, internal communications and strategy in multi-cultural business settings within industries such as MedTech, IT Tech, Construction and Automotive.
See this page for updated shareholdings.
Close
Born
1970
Read bio
Ylva Vihøj
Senior Vice President, Human Resources
Gösta Johannesson
Chairman of the Board and of the Remuneration Committee
Bio:
Born 1959. Board member since 2013. Independent in relation to the company and company management but not independent in relation to the company’s major shareholders.
B.Sc. in Business Administration and Economics. Senior adviser at Bure Equity AB. Other Board assignments: Board member in Yubico AB, Nodica Group and others. Earlier Partner at Provider Venture Partners, before that executive position at Öhman Fondkommission and Handelsbanken Markets.
See this page for updated shareholdings.
Close
Born
1959
Read bio
Gösta Johannesson
Chairman of the Board and of the Remuneration Committee
Emil Billbäck
Member of the Remuneration committee
Bio:
Born 1970. Board member since 2026. Independent in relation to the company and company management but not independent in relation to the company’s major shareholders.
B.Sc. in Business Administration; Economics and Marketing, Karlstad University, Sweden. Most recently CEO of Bonesupport AB (publ.), and prior to that held senior roles at BSN medical GmbH, including Executive Vice President, Chief Commercial Officer and Vice President Global Marketing.
Other Board assignments: None.
See this page for updated shareholdings.
Close
Born
1970
Read bio
Emil Billbäck
Member of the Remuneration committee
Göran Dellgren
Member of the Audit Committee
Bio:
Born 1961. Board member since 2022. Independent in relation to the company, company management and major shareholders.
Thoracic surgeon and a leader in research and development in transplantation nationally and internationally for the past 15 years. Currently Professor of Thoracic Surgery at Sahlgrenska Hospital and Chairman of Department of Surgery at Blekinge Hospital. Göran Dellgren has and has had several assignments, including as chairman of the Swedish Association for Cardiothoracic Surgery, President of the European Society for Heart and Lung Transplantation (ESHLT) and as Director of the International Society for Heart and Lung Transplantation (ISHLT).
See this page for updated shareholdings.
Close
Born
1961
Read bio
Göran Dellgren
Member of the Audit Committee
Anne-Karen Hunt
Member of the Board
Bio:
Born 1977. Independent in relation to the company and company management but not independent in relation to the company’s major shareholders.
Master’s in Business Administration, University of Düsseldorf, Bachelor’s Degree in Marketing and Economics, University of Bayreuth, Germany. Currently President Diagnostics at DEMANT, and prior to that General Manager and President, Ultrasound International, at GE Healthcare, and she has also held senior positions at ABBOTT, TERUMO Interventional Systems and JOHNSON&JOHNSON.
Other Board assignments: None.
See this page for updated shareholdings.
Close
Born
1977
Read bio
Anne-Karen Hunt
Member of the Board
Paul Marcun
Member of the Board
Bio:
Board member since 2025. Independent in relation to the company, company management and major shareholders.
Leading positions at multiple global medical device companies. Most recently Executive Officer and Executive Vice President Growth at Coloplast. Most recent, leading positions at companies such as Getinge, Stryker and Johnson & Johnson. MBA, Corporate Finance and Marketing at University of Technology, Sydney and Bachelor of Veterinary Science at University of Melbourne, Australia.
Other Board assignments: None.
See this page for updated shareholdings.
Close
Born
1966
Read bio
Paul Marcun
Member of the Board
Erik Strömqvist
Member of the Audit Committee
Bio:
Born 1970. Board member since 2023. Independent in relation to the company, company management and major shareholders.
M. Sc. Chemical Engineering. Multiple leading positions in the GE Healthcare Group, most recently as the General Manager of Cyclotrons & TRACERcenter, GE Healthcare. Other Board assignments: Chairman of the Board of Directors in MedTrace Pharma A/S and member of the Board of Directors in Atley Solutions AB, Celcibus AB and Studsvik AB (publ.).
See this page for updated shareholdings.
Close
Born
1970
Read bio
Erik Strömqvist
Member of the Audit Committee
Camilla Öberg
Chairman of the Audit Committee
Bio:
Born 1964. Board member since 2016. Independent in relation to the company, company management and major shareholders.
B.Sc. in Business Administration at Stockholm school of economics. CFO at Yubico AB. Before that CFO at Cybercom and Logica. Other Board assignments: Board member in Instalco.
See this page for updated shareholdings.
Close
Born
1964
Read bio
Camilla Öberg
Chairman of the Audit Committee
Analyst coverage
Latest
Analysts
Stifel
ed.hall@stifel.com
DNB Carnegie
ulrik.trattner@carnegie.se
Danske Bank
simon.larsson@danskebank.se
Pareto Securities
filip.wiberg@paretosec.com
Redeye
johan.unnerus@redeye.se
Handelsbanken
ludwig.germunder@handelsbanken.se
Financial overview
A history of innovation
1998
XVIVO Perfusion founded and research collaboration initiated with Prof. Stig Steen.
1999
Organ Assist founded by Arjan van der Plaats and Professor Gerard Rakhorst
2000
The first EVLP lung transplant performed with STEEN Solution™.
2001
PERFADEX® FDA 510(k) cleared.
2006
STEEN Solution™ CE marked.
2010/2013
Kidney Assist Transport (1st gen) / Liver Assist CE marked
2014
XPS™ approved by FDA under HDE in the US. CE marked on the EU market.
2015
Kidney Assist CE marked.
2017
First heart transplant using a preservation technique developed by XVIVO partner Prof. Stig Steen.
2018
PERFADEX® Plus. FDA 510(k) cleared and CE marked.
2020
Acquisition of Organ Assist XVIVO becomes the first all organ company.
2021
Acquisition of Star Teams. An organ recovery company serving the U.S. market.
2022
Kidney Assist Transport (2nd gen) CE marked and FDA 510(k) cleared.
2022
Acquisition of Avionord Machines & Perfusion, our former Italian distributor.
2024
Acquisition of FlowHawk
Subscribe to press releases
Sign up for instant updates on financial news, reports, and company announcements.
Placeholder
This is some text inside of a div block.
